Healthcare · Healthcare Services
QVM read Cheap on its own multiples Quality Weak, Valuation Undervalued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #55 of 62 in Healthcare Services by market cap -- full peer table on the Financials page.
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 1 Dec 2023 | SAHASRAR CAPITAL PRIVATE LIMITED | Bulk | Buy | 371,570 | 7.8300 | BSE |
| 1 Dec 2023 | MAYUR VIJAY PATWA | Bulk | Buy | 401,000 | 8.1900 | BSE |
| 1 Dec 2023 | GEETANJALI INVESTMENTS | Bulk | Sell | 896,281 | 8.1600 | BSE |
| 24 Nov 2023 | SAHASRAR CAPITAL PRIVATE LIMITED | Bulk | Buy | 350,000 | 9.1200 | BSE |
| 24 Nov 2023 | GEETANJALI INVESTMENTS | Bulk | Sell | 716,159 | 9.1000 | BSE |
| 23 Nov 2023 | GEETANJALI INVESTMENTS | Bulk | Sell | 447,728 | 8.7000 | BSE |
| 27 Mar 2014 | SH AS ENTERPRISES LLP | Bulk | Buy | 400,000 | 3.3600 | BSE |
| 19 Jun 2013 | DIPESH NALINBHAI DAVE | Bulk | Buy | 1,000,000 | 2.0300 | BSE |
| 19 Jun 2013 | GEETANJALI INVESTMENTS | Bulk | Buy | 1,785,488 | 2.0200 | BSE |
| 18 Jun 2013 | GEETANJALI INVESTMENTS | Bulk | Buy | 3,445,350 | 1.9500 | BSE |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 3 Oct 2026 | Company Update | Transgene Biotek Ltd - 526139 - Reg. 32(1) Statement Of Deviation & Variation. |
| 3 Oct 2026 | Company Update | Transgene Biotek Ltd - 526139 - Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015. |
| 3 Oct 2026 | Company Update | Transgene Biotek Ltd - 526139 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 |
| 3 Oct 2026 | Others | Transgene Biotek Ltd - 526139 - Compliance-57 (5) : intimation after the end of quarter |
| 3 Oct 2026 | Others | Transgene Biotek Ltd - 526139 - Compliance-57 (4) : Prior intimation to the beginning of the quarter |
| 3 Oct 2026 | Others | Transgene Biotek Ltd - 526139 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A |
| 2 Oct 2026 | Board Meeting | Transgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 |
| 25 Sep 2026 | Company Update | Transgene Biotek Ltd - 526139 - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, We Wish To Inform You That The Company Has Received Approval From The Registrar Of Companies (ROC), Hyderabad, Telangana, For Extension Of Time For Holding The 36Th Annual General Meeting (AGM) Of The Company For The Financial Year Ended March 31, 2026. |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
